1. Mistinova J, Valacsai F, Varga I. Congenital absence of the portal vein - case report and a review of literature. Clin Anat 2010;23:750-8.

2. Marks C. Developmental basis of the portal venous system. Am J Surg 1969;117:671-81.

3. Abernethy J. Account of two instances of uncommon formation in the viscera of the human body. Phil Trans R Soc Lond B Biol Sci 1793;83:295-9.

4. Hao Y, Hong X, Zhao X. Congenital absence of the portal vein associated with focal nodular hyperplasia of the liver and congenital heart disease: a case report and literature review. Oncol Lett 2015;9:695-700.

5. Morgan G, Superina R. Congenital absence of the portal vein: two cases and a proposed classification system for portosystemic vascular anomalies. J Pediatr Surg 1994;29:1239-41.

6. Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: the model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005;22:1079-89.

7. Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39:503-9.

8. Starzl TE, Francavilla A, Halgrimson CG, Francavilla FR, Porter KA, Brown TH, Putnam CW. The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet 1973;137:179-99.

9. Kamiya S, Taniguchi I, Yamamoto T, Sawamura S, Kai M, Ohnishi N, Tsuda M, Yamamura M, Nakasaki H, Yokoyama S. Analysis of intestinal flora of a patient with congenital absence of the portal vein. FEMS Immunol Med Microbiol 1993;7:73-80.

10. Lundstedt C, Lindell G, Tranberg KG, Svartholm E. Congenital absence of the intrahepatic portion of the portal vein in an adult male resected for hepatocellular carcinoma. Eur Radiol 2001;11:2228-31.

11. Morotti RA, Killackey M, Shneider BL, Repucci A, Emre S, Thung SN. Hepatocellular carcinoma and congenital absence of the portal vein in a child receiving growth hormone therapy for turner syndrome. Semin Liver Dis 2007;27:427-31.

12. Pichon N, Maisonnette F, Pichon-Lefievre F, Valleix D, Pillegand B. Hepatocarcinoma with congenital agenesis of the portal vein. Jpn J Clin Oncol 2003;33:314-6.

13. Hu GH, Shen LG, Yang J, Mei JH, Zhu YF. Insight into congenital absence of the portal vein: is it rare? World J Gastroenterol 2008;14:5969-79.

14. Reynolds AR, Furlan A, Fetzer DT, Sasatomi E, Borhani AA, Heller MT, Tublin ME. Infiltrative hepatocellular carcinoma: what radiologists need to know. Radiographics 2015;35:371-86.

15. Thian YL, Low AS, Chow PK, Ooi LL, Chung AY, Low SC, Xie W, Thng CH. Atypical enhancement pattern of hepatocellular carcinoma with portal vein thrombosis on multiphasic CT. Ann Acad Med Singapore 2011;40:454-9.

16. Lam A, Fernando D, Sirlin CC, Nayyar M, Goodwin SC, Imagawa DK, Lall C. Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation. Clin Radiol 2017;72:994.e9-16.

17. Furlan A, Marin D, Vanzulli A, Patera GP, Ronzoni A, Midiri M, Bazzocchi M, Lagalla R, Brancatelli G. Hepatocellular carcinoma in cirrhotic patients at multidetector CT: hepatic venous phase versus delayed phase for the detection of tumour washout. Br J Radiol 2011;84:403-12.

18. Monzawa S, Ichikawa T, Nakajima H, Kitanaka Y, Omata K, Araki T. Dynamic CT for detecting small hepatocellular carcinoma: usefulness of delayed phase imaging. AJR Am J Roentgenol 2007;188:147-53.

19. López-Larramona G, Lucendo AJ, González-Castillo S, Tenias JM. Hepatic osteodystrophy: an important matter for consideration in chronic liver disease. World J Hepatol 2011;3:300-7.

20. Lange PA, Stoller JK. The hepatopulmonary syndrome: effect of liver transplantation. Clin Chest Med 1996;17:115-23.

21. Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology 2013;84:311-8.

22. Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, Boige V, Malka D, Leboulleux S, Ducreux M, Baudin E, Deschamps F. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol 2015;38:372-80.

23. Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2017;27:526-35.

24. Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. Transarterial chemoembolization for the treatment of advanced-stage hepatocellular carcinoma. J Gastrointest Surg 2016;20:2002-9.

25. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson AB 3rd, Salem R. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and surivival. J Clin Oncol 2009;27:5734-42.

26. Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Determinants of alpha-fetoprotein levels in patients with hepatocelular carcinoma: implications for its clinical use. Cancer 2014;120:2150-7.

27. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges and clinical perspectives. Hepatology 2013;58:2188-97.

28. Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009;20:1121-30.

29. Verslype C, Rosmorduc O, Rougier P; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii41-8.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: